Treatment > Teniposide


Glioblastoma


Dirk Vordermark, Klemens Ruprecht, Peter Rieckmann, Wolfgang Roggendorf, Giles H Vince, Monika Warmuth-Metz, Oliver Kölbl, and Michael Flentje
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26)
BMC Cancer. 2006 Oct 18;6:247
Abstract | Full Text | Reprint


Gliomas


Lynn G. Feun, Angela Marini, Howard Landy, Arnold Markoe, Deborah Heros, Carlos Robles, Cristina Herrera and Niramol Savaraj
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors
J Neurooncol. 2006 Oct 19; [Epub ahead of print]
Abstract

The Neuro-Oncology Working Group Of The German Cancer Society
Neuro-oncology working group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma
J Clin Oncol. 2003 Sep 1;21(17):3276-84 (PDF Full Text)


Oligodendrogliomas


A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo, S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini and M. Ermani
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
Annals of Oncology 14:1727-1731, December 2003 

 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
|
Children's Corner | E-mail Alerts | Journals | Newsletter | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP